ArticleChina CDC weekly2025
Two-Year Surveillance of Dengue, Zika, and Chikungunya Viruses Among Chinese Blood Donors - Guangxi and Yunnan PLADs, China, 2022-2023.
Article in China CDC weekly, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Review
- Honghe Bunya-like virus: a novel virus identified in mosquitoes from Yunnan, China.BMC genomics · 2026Article
- Diagnostic and genomic characterization of an imported chikungunya virus case in Ningxia Hui Autonomous Region, China, September 2025.Infectious medicine · 2026Article
- Emergence of Two New Lineages of the Cosmopolitan Dengue Virus Serotype 2 in Yunnan, China, 2024.The Journal of infectious diseases · 2026Article
- Integrating national evidence with global standards: China's updated dengue and chikungunya diagnosis and treatment plans.Infectious diseases & immunity · 2026Article
- Molecular confirmation of transfusion-transmitted dengue virus infection following platelet transfusion in the Chinese mainland.Frontiers in cellular and infection microbiology · 2026Article
- Editorial: Global infectious disease surveillance technologies and data sharing protocols.Frontiers in public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
What is already known about this topic?: The transmission of emerging and re-emerging arboviruses represent a critical challenge to blood transfusion safety worldwide. What is added by this report?: This study established a comprehensive quality assurance system for Dengue virus (DENV), Zika virus (ZIKV), and Chikungunya virus (CHIKV) nucleic acid testing (NAT) blood screening. The system included external quality assessment (EQA) implementation across all participating central blood stations and performance evaluation of six domestic blood screening reagents. Surveillance conducted in Yunnan Province and Guangxi Zhuang Autonomous Region revealed no positive cases among 45,383 blood samples screened in 2022. In 2023, screening of 44,972 blood donors identified 9 NAT-reactive samples at the Xishuangbanna central blood station, with 6 confirmed as DENV-1 positive. What are the implications for public health practice?: Blood stations in border regions must implement comprehensive surveillance systems with enhanced detection sensitivity and robust early warning mechanisms to effectively address emerging disease threats and ensure transfusion safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.